Technology ID
TAB-3793
Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS)
E-Numbers
E-139-2020-0
Lead Inventor
Burbelo, Peter (NIDCR)
Co-Inventors
Cohen, Jeffrey (NIAID)
Applications
Therapeutics
Therapeutic Areas
Infectious Disease
Immunology
Research Products
Antibodies
Lead IC
NIDCR
ICs
NIDCR
NIAID
This technology includes an immunoassay to measure SARS-CoV-2 antibodies against the nucleocapsid and spike proteins. Using the luciferase immunoprecipitation technology (LIPS), this highly quantitative test for nucleocapsid antibodies showed 100% sensitivity and 100% specificity with COVID-19 patient samples from fifteen or more days after symptom onset, and antibodies against SARS-CoV-2 spike protein were detected with 91% sensitivity and 100% specificity These assays have a high degree of sensitivity and specificity and should have commercial application related to seroepidemiologic studies and developing biomarkers for COV1D-19 disease.
Commercial Applications
Diagnostic test for COVID-19.
Competitive Advantages
Unlike standard ELISA assays, LIPS assays are more likely to identity antibodies to conformational dependent antibodies, to correlate well with neutralizing antibody responses, and have a dynamic range up to 7 10910 for some antigens. LIPS assays require 5 uL of sera which can be obtained from a finger stick.
Licensing Contact: